UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’
Start-Up Raises $17.5m In Series A
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
You may also be interested in...
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
Timing means full EU approval could coincide with US FDA authorization later this year.